IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 29; no. 1; pp. 135 - 144
• Main Authors: Tagliaferri, Annarita, Molinari, Angelo Claudio, Peyvandi, Flora, Coppola, Antonio, Demartis, Francesco, Biasoli, Chiara, Borchiellini, Alessandra, Cultrera, Dorina, De Cristofaro, Raimondo, Daniele, Filomena, Giordano, Paola, Marchesini, Emanuela, Margaglione, Maurizio, Marino, Renato, Pollio, Berardino, Radossi, Paolo, Santoro, Cristina, Santoro, Rita Carlotta, Siragusa, Sergio, Sottilotta, Gianluca, Tosetto, Alberto, Piscitelli, Lydia, Villa, Maria Rosaria, Zanon, Ezio, Finardi, Adele, Schiavetti, Irene, Vaccari, Daniella, Castaman, Giancarlo
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.01.2023; John Wiley and Sons Inc
• Subjects: ABR; Adult; Albumin; Albumins; annual consumption; Bleeding; Coagulation factor IX; Coagulation factors; Disease prevention; Dosage; extended half‐life FIX; Factor IX - therapeutic use; Factor IX deficiency; Fusion protein; Hemophilia; Hemophilia B - drug therapy; Hemorrhage - drug therapy; Hemorrhage - prevention & control; Humans; infusion frequency; Italy; Male; Original; Patients; Prophylaxis; Prospective Studies; real life; Recombinant Fusion Proteins - therapeutic use; Retrospective Studies; Trough levels; Italy; infusion frequency; ABR; Trough levels; real life; annual consumption; extended half-life FIX

Introduction Factor IX replacement therapy is used for treatment and prophylaxis of bleeding in haemophilia B. rIX‐FP is an extended half‐life albumin‐fusion protein, which, in clinical studies, has demonstrated prolonged dosing intervals up to 21 days for routine prophylaxis, providing therapeutic...